21530492|t|Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation.
21530492|a|Alzheimer's disease (AD), which is characterized by progressive cognitive impairment, is the most common neurodegenerative disease. Here, we investigated the preventive effect of a phosphodiesterase III inhibitor, cilostazol against cognitive decline in AD mouse model. In vitro studies using N2a cells stably expressing human amyloid precursor protein Swedish mutation (N2aSwe) showed that cilostazol decreased the amyloid beta (Abeta) levels in the conditioned medium and cell lysates. Cilostazol attenuated the expression of ApoE, which is responsible for Abeta aggregation, in N2aSwe. Intracerebroventricular injection of Abeta(25-35) in C57BL/6J mice resulted in increased immunoreactivity of Abeta and p-Tau, and microglia activation in the brain. Oral administration of cilostazol for 2 weeks before Abeta administration and once a day for 4 weeks post-surgery almost completely prevented the Abeta-induced increases of Abeta and p-Tau immunoreactivity, as well as CD11b immunoreactivity. However, post-treatment with cilostazol 4 weeks after Abeta administration, when Abeta was already accumulated, did not prevent the Abeta-induced neuropathological responses. Furthermore, cilostazol did not affect the neprilysin and insulin degrading enzymes involved in the degradation of the Abeta peptide, but decreased ApoE levels in Abeta-injected brain. In addition, cilostazol significantly improved spatial learning and memory in Abeta-injected mice. The findings suggest that a phosphodiesterase III inhibitor, cilostazol significantly decreased Abeta accumulation and improved memory impairment induced by Abeta(25-35). The beneficial effects of cilostazol might be explained by the reduction of Abeta accumulation and tau phosphorylation, not through an increase in Abeta degradation but via a significant decrease in ApoE-mediated Abeta aggregation. Cilostazol may be the basis of a novel strategy for the therapy of AD.
21530492	57	67	cilostazol	Chemical	MESH:D000077407
21530492	71	83	amyloid beta	Gene	351
21530492	92	110	cognitive deficits	Disease	MESH:D003072
21530492	137	149	amyloid beta	Gene	351
21530492	164	183	Alzheimer's disease	Disease	MESH:D000544
21530492	185	187	AD	Disease	MESH:D000544
21530492	228	248	cognitive impairment	Disease	MESH:D003072
21530492	269	294	neurodegenerative disease	Disease	MESH:D019636
21530492	378	388	cilostazol	Chemical	MESH:D000077407
21530492	397	414	cognitive decline	Disease	MESH:D003072
21530492	418	420	AD	Disease	MESH:D000544
21530492	421	426	mouse	Species	10090
21530492	457	460	N2a	CellLine	CVCL:0470
21530492	485	490	human	Species	9606
21530492	491	516	amyloid precursor protein	Gene	351
21530492	535	541	N2aSwe	CellLine	CVCL:0470
21530492	555	565	cilostazol	Chemical	MESH:D000077407
21530492	580	592	amyloid beta	Gene	351
21530492	594	599	Abeta	Gene	351
21530492	652	662	Cilostazol	Chemical	MESH:D000077407
21530492	723	728	Abeta	Gene	351
21530492	745	751	N2aSwe	CellLine	CVCL:0470
21530492	790	802	Abeta(25-35)	Gene	11820
21530492	815	819	mice	Species	10090
21530492	862	867	Abeta	Gene	11820
21530492	941	951	cilostazol	Chemical	MESH:D000077407
21530492	971	976	Abeta	Gene	11820
21530492	1064	1069	Abeta	Gene	11820
21530492	1091	1096	Abeta	Gene	11820
21530492	1136	1141	CD11b	Gene	16409
21530492	1189	1199	cilostazol	Chemical	MESH:D000077407
21530492	1214	1219	Abeta	Gene	11820
21530492	1241	1246	Abeta	Gene	11820
21530492	1292	1297	Abeta	Gene	11820
21530492	1348	1358	cilostazol	Chemical	MESH:D000077407
21530492	1378	1388	neprilysin	Gene	17380
21530492	1454	1459	Abeta	Gene	11820
21530492	1498	1503	Abeta	Gene	11820
21530492	1533	1543	cilostazol	Chemical	MESH:D000077407
21530492	1598	1603	Abeta	Gene	11820
21530492	1613	1617	mice	Species	10090
21530492	1680	1690	cilostazol	Chemical	MESH:D000077407
21530492	1715	1720	Abeta	Gene	11820
21530492	1747	1764	memory impairment	Disease	MESH:D008569
21530492	1776	1788	Abeta(25-35)	Gene	11820
21530492	1816	1826	cilostazol	Chemical	MESH:D000077407
21530492	1866	1871	Abeta	Gene	11820
21530492	1937	1942	Abeta	Gene	11820
21530492	2003	2008	Abeta	Gene	11820
21530492	2022	2032	Cilostazol	Chemical	MESH:D000077407
21530492	2089	2091	AD	Disease	MESH:D000544
21530492	Positive_Correlation	11820	351
21530492	Positive_Correlation	MESH:D003072	351
21530492	Association	MESH:D000544	351
21530492	Positive_Correlation	MESH:D000544	11820
21530492	Association	11820	17380
21530492	Negative_Correlation	MESH:D000077407	351
21530492	Negative_Correlation	MESH:D000077407	MESH:D003072
21530492	Negative_Correlation	MESH:D000077407	16409
21530492	Negative_Correlation	MESH:D000077407	11820
21530492	Positive_Correlation	MESH:D008569	11820
21530492	Positive_Correlation	MESH:D003072	11820
21530492	Negative_Correlation	MESH:D000077407	MESH:D000544
21530492	Positive_Correlation	MESH:D000077407	MESH:D008569
21530492	Positive_Correlation	11820	16409

